DeepNewz, mobile.

People-sourced. AI-powered. Unbiased News.

Screenshot of DeepNewz app showing story detail view.

Screenshot of DeepNewz app showing story list view.

IO Biotech News

IO Biotech’s Cylembio Plus KEYTRUDA Shows 19.4-Month PFS Improvement in Phase 3 Melanoma Trial, Eyes FDA Approval Talks

Prediction Markets

IO Biotech’s Cylembio Plus KEYTRUDA Shows 19.4-Month PFS Improvement in Phase 3 Melanoma Trial, Eyes FDA Approval Talks

14

3 days ago

Latest stories